

Perseus Proteomics Inc.

30-1 Nihonbashi-hakozakicho, Chuo-ku,

Tokyo, 103-0015, Japan

TEL: +81-3-6264-8268 FAX: +81-3-3668-7776

<https://www.ppmx.com>

order@ppmx.com

Anti human SF-1 mouse monoclonal antibody (Protein A purified)

SF-1: Steroidogenic factor 1

Code No. PP-N1665-0C

Clone No. N1665

RRID AB_3753408

Isotype IgG1

Host mouse

Conjugate none

Alias NR5A1, AD4BP, ELP, FTZ1, FTZF1, SF1

UniProt ID Q13285

Entrez Gene ID 2516 (human)

Specificity This antibody specifically recognizes human SF-1 and cross-reacts with mouse and rat SF-1.

Immunogen *E. coli*-expressed recombinant human SF-1 (218–461 aa).

Concentration 1 mg/mL

Volume 100 µL

Formulation Physiological saline with 0.1% sodium azide as a preservative.

Purification Protein A affinity chromatography

Origin Produced in serum-free medium using a hybridoma generated by fusion of mouse myeloma cells (NS-1) with splenocytes from a BALB/c mouse immunized with *E. coli*-expressed recombinant human SF-1 (218–461 aa).

Storage Store at 2–8°C for up to one month. For long-term storage, aliquot and store at –20°C or below. Repeated freezing and thawing should be avoided, as it may cause degradation and result in reduced performance.

Notes Sodium azide may react with lead and copper plumbing to form explosive metal azides. Flush with large amounts of water during disposal.

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Not for Diagnostic or Therapeutic use. Purchase of this product does not include or carry any right to resell or transfer this product either as a standalone product or as a component of another product. Any use of this product other than the permitted use without the express written consent of Perseus Proteomics Inc. is prohibited.

Application	Recommended Conc. *	Data †	References ‡
ChIP (Chromatin immunoprecipitation)	—	—	11
IHC-P (Immunohistochemistry-Paraffin)	10 µg/mL	Fig. 1	5,7,8,9,12,14,16,22
IHC-P (IF) (Immunohistochemistry-Paraffin, Immunofluo.)	—	—	21,23
IHC-Fr (IF) (Immunohistochemistry-Frozen, Immunofluo.)	—	—	15,18,20,21
ICC-IF (Immunocytochemistry, Immunofluorescence)	—	—	24
IP (Immunoprecipitation)	decide by use	—	—
ELISA	0.1 µg/mL	Fig. 2	—
WB (Western Blot)	3 µg/mL	—	2,6
WB (Western Blot- Non-Reducing)	3 µg/mL	—	—

* : Optimal dilutions/concentrations should be determined by the user.

† : Data figures are shown on page 2.


‡ : References are listed on page 3.



Full online PDF datasheet available here


Application Data

Fig. 1 IHC-P (Immunohistochemistry-Paraffin)



Section : Paraffin, Fixation : 10% formalin-fixed in immersion
Activation : Autoclave (121°C, 15min), Blocking with 3% H₂O₂ in methanol
Primary Antibody : PP-N1665-0C 3–20 µg/mL

Fig. 2 Antigen-coated ELISA



Wells were coated with **human SF-1 (218–461 aa; expressed in *E. coli*)** at 10 µg/well overnight at 4°C. After blocking with non-fat dry milk for 1 h at room temperature (RT) and washing, serially diluted **anti-SF-1 antibody (N1665)** solutions were added to each well and incubated at RT. The plate was washed, incubated with HRP-conjugated anti-mouse IgG (1:15,000) at RT, washed again, and visualized with TMB reagent.

References

1. Suh JM, et al. Mol Endocrinol. 2006;20(12):3412-3420. [PMID: 16973757](#)
2. Guo G, Smith A. Development. 2010;137(19):3185-3192. [PMID: 20823062](#)
3. Sbiera S, et al. J Clin Endocrinol Metab. 2010;95(10):E161-E171. [PMID: 20660055](#)
4. Almeida MQ, et al. J Clin Endocrinol Metab. 2010;95(3):1458-1462. [PMID: 20080844](#)
5. Hong SW, et al. Front Oncol. 2021;11:739290. [PMID: 34589436](#)
6. Suda N, et al. Endocrinology. 2011;152(6):2266-2277. [PMID: 21467194](#)
7. Noël JC, Anaf V, et al. Fertil Steril. 2011;95(8):2655-2657. [PMID: 21324456](#)
8. Yasuno H, et al. J Toxicol Pathol. 2013;26(2):209-213. [PMID: 23914064](#)
9. Duregon E, et al. Hum Pathol. 2013;44(5):822-828. [PMID: 23158211](#)
10. Takai Y, et al. J Toxicol Pathol. 2013;26(3):319-323. [PMID: 24155566](#)
11. Doghman M, et al. Nucleic Acids Res. 2013;41(19):8896-8907. [PMID: 23907384](#)
12. Hattori Y, et al. J Ovarian Res. 2015;8:73. [PMID: 26576867](#)
13. Nishioka H, et al. Endocr Pathol. 2015;26(4):349-355. [PMID: 26481628](#)
14. Ishida K, et al. Pathol Int. 2016;66(5):281-287. [PMID: 27060902](#)
15. Corman TS, et al. Development. 2018;145(21):dev167379. [PMID: 30291164](#)
16. Kato Y, et al. J Toxicol Pathol. 2019;32(2):101-104. [PMID: 31092976](#)
17. Dhakal HP, et al. Am J Surg Pathol. 2019;43(8):1123-1128. [PMID: 31094926](#)
18. Zhou X, et al. Nat Commun. 2020;11(1):4063. [PMID: 32792525](#)
19. Nishikido A, et al. Mol Cell Endocrinol. 2020;501:110657. [PMID: 31751625](#)
20. Sasaki K, et al. Cell Rep. 2021;35(5):109075. [PMID: 33951437](#)
21. Sakata Y, et al. Dev Cell. 2022;57(22):2566-2583.e8. [PMID: 36413950](#)
22. Asa SL, et al. Endocr Pathol. 2024;35(4):349-353. [PMID: 39579326](#)
23. Neirijnck Y, et al. Cell Rep. 2023;42(3):112191. [PMID: 36862551](#)
24. Danti L, et al. J Ovarian Res. 2023;16(1):194. [PMID: 37726790](#)